Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a life sciences company that provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats globally. Its business is organized into Commercial Products, MCM Products, and All Other Revenues segments. The company offers a range of vaccines and therapeutics, including ACAM2000 for smallpox and mpox, BioThrax and CYFENDUS for anthrax, Ebanga for Ebola, and TEMBEXA for smallpox. It also provides opioid overdose reversal products such as NARCAN and KLOXXADO nasal sprays. Additionally, Emergent offers contract development and manufacturing services, including drug substance and product manufacturing, packaging, and process development.

Emergent BioSolutions Inc. is listed on the New York Stock Exchange (NYSE) under the ticker symbol EBS. Its shares are traded in US Dollars (USD). The company is headquartered in the United States and operates primarily in the US market, though its products address global public health threats.

Emergent BioSolutions Inc. operates in the Healthcare sector and is classified under the Drug Manufacturers - Specialty & Generic industry. This means the company focuses on developing and manufacturing specialized pharmaceutical products, including vaccines and therapeutics for public health threats, rather than broad-market drugs.

Emergent BioSolutions offers a diverse portfolio of medical countermeasures and commercial products. Key products include ACAM2000 (smallpox and mpox vaccine), ANTHRASIL (inhalational anthrax treatment), BAT (botulism antitoxin), BioThrax and CYFENDUS (anthrax vaccines), Ebanga (Ebola treatment), Raxibacumab (anthrax monoclonal antibody), TEMBEXA (smallpox antiviral), and CNJ-016 (smallpox vaccination complication treatment). For opioid overdose, it provides NARCAN and KLOXXADO nasal sprays. The company also offers contract development and manufacturing services, including drug substance and product manufacturing, packaging, technology transfer, and analytical development.

Emergent BioSolutions generates revenue through three segments: Commercial Products, MCM Products, and All Other Revenues. The Commercial Products segment includes sales of opioid overdose reversal products like NARCAN and KLOXXADO. The MCM Products segment covers sales of medical countermeasures such as vaccines and therapeutics for anthrax, smallpox, botulism, and Ebola. The All Other Revenues segment includes contract development and manufacturing services, where the company produces drug substances and products for other organizations, along with packaging, technology transfer, and process development services.